Abstract: A method includes receiving data representing graphomotor motion during a succession of executions of graphomotor diagnostic tasks performed in a medical context by a subject, processing the received data using a computer, including determining a first set of quantitative features from a first execution of a task by the subject, and determining a second set of quantitative features from a second execution of a task by the subject, determining one or more metrics based on a comparison to the successive executions, including using at least the first set of quantitative features and the second set of quantitative features to determine said metrics, and providing a diagnostic report associated with neurocognitive mechanisms underlying the subject's execution of the tasks based on the determined metrics.

Abstract: A method includes receiving data representing graphomotor motion during a succession of executions of graphomotor diagnostic tasks performed in a medical context by a subject, processing the received data using a computer, including determining a first set of quantitative features from a first execution of a task by the subject, and determining a second set of quantitative features from a second execution of a task by the subject, determining one or more metrics based on a comparison to the successive executions, including using at least the first set of quantitative features and the second set of quantitative features to determine said metrics, and providing a diagnostic report associated with neurocognitive mechanisms underlying the subject's execution of the tasks based on the determined metrics.

Abstract: A method includes receiving data representing graphomotor motion during a succession of executions of graphomotor diagnostic tasks performed in a medical context by a subject, processing the received data using a computer, including determining a first set of quantitative features from a first execution of a task by the subject, and determining a second set of quantitative features from a second execution of a task by the subject, determining one or more metrics based on a comparison to the successive executions, including using at least the first set of quantitative features and the second set of quantitative features to determine said metrics, and providing a diagnostic report associated with neurocognitive mechanisms underlying the subject's execution of the tasks based on the determined metrics.

Abstract: Trapping devices and methods are provided for capturing a medical analyte, in blood or another biological fluid. The device may include a structural substrate and a binding agent, such as an antibody, affixed to the structural substrate, wherein the binding agent is capable of binding or attaching with a medical analyte, such as a viral particle, and the device is configured for placement in a biological cavity or vessel (containing a biological fluid) in a patient. The trapping device, which may be in a twisted coil shape, is configured to trap at least some of the medical analyte, such a viral particle, present in the biological fluid. The method may include deploying a trapping device into the patient's blood vessel; after a period following the deployment, removing the trapping device from the biological cavity or blood vessel; and then analyzing the trapping device for the presence of the medical analyte.

Abstract: A method includes receiving data representing graphomotor motion during a succession of executions of graphomotor diagnostic tasks performed in a medical context by a subject, processing the received data using a computer, including determining a first set of quantitative features from a first execution of a task by the subject, and determining a second set of quantitative features from a second execution of a task by the subject, determining one or more metrics based on a comparison to the successive executions, including using at least the first set of quantitative features and the second set of quantitative features to determine said metrics, and providing a diagnostic report associated with neurocognitive mechanisms underlying the subject's execution of the tasks based on the determined metrics.

Abstract: Trapping devices and methods are provided for capturing a medical analyte, in blood or another biological fluid. The device may include a structural substrate and a binding agent, such as an antibody, affixed to the structural substrate, wherein the binding agent is capable of binding or attaching with a medical analyte, such as a viral particle, and the device is configured for placement in a biological cavity or vessel (containing a biological fluid) in a patient. The trapping device, which may be in a twisted coil shape, is configured to trap at least some of the medical analyte, such a viral particle, present in the biological fluid. The method may include deploying a trapping device into the patient's blood vessel; after a period following the deployment, removing the trapping device from the biological cavity or blood vessel; and then analyzing the trapping device for the presence of the medical analyte.

Abstract: Methods are provided for detecting lipid cores underneath thin fibrous caps (LCTC) and thin-cap fibroatheromas (TCFA) in a subject in need of diagnosis for having a vulnerable plaque, a plaque at risk of disruption or thrombosis, or risk of an acute coronary syndrome, and for screening compounds for modulators of this process.

Abstract: Disclosed is an apparatus and corresponding method to capture individual representational motions made by a person while performing a neuropsychological test. A user of the apparatus and method may be allowed to view, edit, classify, and retrieve any captured and recorded motions made by the person. In one embodiment, a capture unit, such as a digitizer, captures the motions made by a person while performing a Clock Drawing Test, and the captured data may then be reported in a myriad of ways. The apparatus and method also provide a means to standardize administration and scoring of writing utensil and paper based neuropsychological testing administered to a person or control and test groups for domestic or international applications. By analyzing individual representational motions made by a person while performing a neuropsychological test, unexpectedly more information may be gleaned from the test than was available to physicians from only a completed drawing.

Abstract: Trapping devices and methods are provided for capturing a medical analyte, in blood or another biological fluid. The device may include a structural substrate and a binding agent, such as an antibody, affixed to the structural substrate, wherein the binding agent is capable of binding or attaching with a medical analyte, such as a viral particle, and the device is configured for placement in a biological cavity or vessel (containing a biological fluid) in a patient. The trapping device, which may be in a twisted coil shape, is configured to trap at least some of the medical analyte, such a viral particle, present in the biological fluid. The method may include deploying a trapping device into the patient's blood vessel; after a period following the deployment, removing the trapping device from the biological cavity or blood vessel; and then analyzing the trapping device for the presence of the medical analyte.

Abstract: A system for transferring spinal cord signals comprises a superior electrode and an inferior electrode. The superior electrode interfaces with a first portion of a spinal cord of a human body; and the inferior electrode interfaces with a second portion of the spinal cord. The superior electrode has at least one superior contact for receiving signals from the first portion of the spinal cord to transmit to the inferior electrode; and the inferior electrode has at least one inferior contact for transmitting signals received from the superior electrode to the second portion of the spinal cord.

Abstract: Methods are provided for detecting lipid cores underneath thin fibrous caps (LCTC) and thin-cap fibroatheromas (TCFA) in a subject in need of diagnosis for having a vulnerable plaque, a plaque at risk of disruption or thrombosis, or risk of an acute coronary syndrome, and for screening compounds for modulators of this process.